Furthermore, combining DCZ0415 and olaparib (a poly [ADP-ribose] polymerase [PARP1] inhibitor) has synergistic anticancer effects against hepatocellular carcinoma cells [51]. Here, PARP1 is linked to hepatocellular carcinoma.